Cost effectiveness of competing strategies to prevent or treat GORD- related dysphagia

PharmacoEconomics

Volumn 17, Issue 4, 2000, Pages 391-401

  Sonnenberg, Amnon ^a,b  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM MAGNESIUM HYDROXIDE; ANTACID AGENT; CIMETIDINE; CISAPRIDE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; PROKINETIC AGENT; PROPANTHELINE BROMIDE; PROTON PUMP INHIBITOR; SUCRALFATE;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DYSPHAGIA; GASTROESOPHAGEAL REFLUX; HUMAN; LIFESTYLE; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; SMOKING CESSATION; TREATMENT OUTCOME; WEIGHT REDUCTION;

EID: 0034055716     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200017040-00009     Document Type: Article

References (33)

1. 1. Pope II CE. Acid reflux disorders. N Engl J Med 1994; 331: 1800-2
2. 2. Kahrilas PJ. Gastroesophageal reflux disease. JAMA 1996; 276: 983-8
3. 3. Fennerty MB, Castell D, Fendrick AM, et al. The diagnosis and treatment of gastroesophageal reflux disease in a managed care environment. Arch Intern Med 1996; 156: 477-84
4. 4. Orlando RC. The pathogenesis of gastroesophageal reflux disease: the relationship between epithelial defense, dysmotility, and acid exposure. Am J Gastroenterol 1997; 92: 3S-7S
5. 5. Jacob P, Kahrilas PJ, Vanagunas A. Peristaltic dysfunction associated with nonobstructive dysphagia in reflux disease. Dig Dis Sci 1990; 35: 939-42
6. 6. Pauker SG, Kassirer JP. Decision analysis. N Engl J Med 1987; 316: 250-8
7. 7. Bossel H. Modeling and stimulation. Wellesley (MA): AK Peters, 1994
8. 8. Modlin IM, Sachs G. Acid related diseases: biology and treatment. Konstanz: Schnetztor Verlag, 1998
9. 9. Holloway RH, Hongo M, Berger K, et al. Gastric distension: a mechanism for postprandial gastroesophageal reflux. Gastroenterology 1985; 89: 779-84
10. 10. Velasco N, Hill LD, Gannan RM, et al. Gastric emptying and gastroesophageal reflux. Effects of surgery and correlation with esophageal motor function. Am J Surg 1982; 144: 58-62
11. 11. Parkman HP, Schwartz SS. Esophagitis and gastroduodenal disorders associated with diabetic gastroparesis. Arch Intern Med 1987; 147: 1477-80
12. 12. Sonnenberg A, Steinkamp U, Weise A, et al. Salivary secretion in reflux esophagitis. Gastroenterology 1982; 83: 889-95
13. 13. Helm JF, Dodds WJ, Pelc LR, et al. Effect of esophageal emptying and saliva on clearance of acid from the esophagus. N Engl J Med 1984; 310: 284-8
14. 14. Lin S, Ke M, Xu J, et al. Impaired esophageal emptying in reflux disease. Am J Gastroenterol 1994; 89: 1003-6
15. 15. Kjellén G, Tibbling L. Influence of body position, dry and water swallows, smoking, and alcohol on esophageal acid clearing. Scand J Gastroenterol 1978; 13:283-8
16. 16. Harvey RF, Gordon PC, Hadley N, et al. Effects of sleeping with bed-head raised and of ranitidine in patients with severe peptic oesophagitis. Lancet 1987; II: 1200-3
17. 17. El-Serag HB, Sonnenberg A. Non-steroidal anti-inflammatory drugs represent risk factors of erosions and peptic strictures of the esophagus. Am J Gastroenterol 1997; 92: 57-60
18. 18. Kahrilas PJ, Dodds WJ, Hogan WJ, et al. Esophageal peristaltic dysfunction in peptic esophagitis. Gastroenterology 1986; 91: 897-904
19. 19. Geldof H, Hazelhoff B, Otten MH. Two different dose regimens of cisapride in the treatment of reflux esophagitis: a double-blind comparison with ranitidine. Aliment Pharmacol Ther 1993; 7: 409-15
20. 20. Galmiche JP, Barthelemy P, Hamelin B. Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. Aliment Pharmacol Ther 1997; 11: 765-73
21. 21. Bremner CG, Marks IN, Segal I, et al. Reflux esophagitis therapy: sucralfate versus ranitidine in a double blind multicenter trial. Am J Med 1991; 91 Suppl. 2A: 119S-22S
22. 22. Chiba N, De Gara J, Wilkinson JM, et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798-810
23. 23. Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995; 333: 1106-10
24. 24. De Vault KR, Castell DO, Practice Parameters Committee of the American College of Gastroenterology. Guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Arch Intern Med 1995; 155: 2165-73
25. 25. Wo JM, Waring JP. Medical therapy of gastroesophageal reflux and management of esophageal strictures. Surg Clin North Am 1997; 77: 1041-62
26. 26. Cardinale V, editor. Red Book. Montvale (NJ): Medical Economics Company, 1998
27. 27. Kuo WH, Kalloo AN. Reflux strictures of the esophagus. Gastrointest Endosc Clin N Am 1998; 8: 273-81
28. 28. Kirschner CG, Davis SJ, Evans D, et al. Current procedural terminology CPT 1999. Chicago (IL):American Medical Association, 1999
29. 29. Siegel JE, Weinstein MC, Torrance GW. Reporting cost-effectiveness studies and results. In: Gold MR, Siegel JE, Russel LB, et al., editors. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996: 276-303
30. 30. Drummond MF, O'Brien B, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. 2nd ed. Chapter 5: Cost-effectiveness analysis. New York: Oxford University Press, 1997: 96-138
31. 31. Miller LS, Vinayek R, Frucht H, et al. Reflux esophagitis in patients with Zollinger-Ellison syndrome. Gastroenterology 1990; 98: 341-6
32. 32. Saladin TA, French AB, Zarasafonetis CJD, et al. Esophageal motor abnormalities in scleroderma and related diseases. Am J Dig Dis 1966; 11: 522-35
33. 33. Schwartz WB. Decision analysis: a look at the chief complaints. N Engl J Med 1979; 300: 556-9